ArticleInternational journal of nanomedicine2025
CD42-Enriched Extracellular Vesicles Contribute to Increased Platelet Aggregation and Possibly Organ Damage in Patients with Burn Injury Complicated by Sepsis.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Decoding Immune Dysregulation in Sepsis Through Extracellular Vesicles: A Path to Precision Medicine.Pharmaceutics · 2026Review
- Extracellular Vesicle-Derived MicroRNAs' Value in Diagnosing and Predicting Clinical Outcomes in Patients with COVID-19 and Bacterial Sepsis.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis is the leading cause of death in patients with burn injury, in whom it represents a real diagnostic challenge. Here, we studied extracellular vesicles (EVs) released during sepsis in burn patients by multiplexed phenotyping and explored their role in promoting platelet aggregation. Methods: We enrolled 33 burn patients, 23 with (Burn Septic Patients - BSP) and 10 without sepsis (Burn Non-Septic Patients - BnSP), and 10 healthy subjects (HS). EVs, isolated by ultracentrifugation or precipitation-based methods, were characterized by Nanoparticle Tracking Analysis, Transmission Electron Microscopy, and flow cytometry, and their surface antigens studied by bead-based multiplex flow cytometry. Platelet aggregation was studied in platelet-rich plasma using light-transmission aggregometry. Results: EVs from BSP expressed a specific pattern of epitopes distinct from those from BnSP and HS. Specifically, EVs from BSP showed an increase in CD42a expression compared to BnSP-(p<0.05) and HS-(p<0.0001) derived EVs. Moreover, CD42a-EVs expression increased according to sepsis severity in BSP. In vitro, EVs from BSP, but not from HS, primed platelet aggregation, an effect reduced by an anti-CD42 neutralizing monoclonal antibody. Conclusion: Our results suggest the potential of CD42a-enriched EVs as diagnostic and prognostic markers of sepsis in burn patients and their role in increasing platelet activation in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.